NCT05444569View on ClinicalTrials.gov

A Study of LY3537021 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions

Healthy

Interventions

DRUG

LY3537021

Administered SC.

DRUG

Liraglutide

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

138623

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY